Piper Sandler Maintains Overweight on Insulet, Lowers Price Target to $250
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on Insulet (NASDAQ:PODD), but lowered the price target from $325 to $250.
November 03, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Insulet's price target has been lowered from $325 to $250 by Piper Sandler, although the Overweight rating is maintained.
The lowering of the price target by Piper Sandler indicates a potential decrease in the stock's value in the short term. However, the maintenance of the Overweight rating suggests that the stock is still expected to outperform the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100